Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact
- DOI
- 10.1016/j.ejca.2026.117789
- Published
- 2026-10
- Container
- European Journal of Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.117789,
title = {Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact},
author = {Rebecca Schou Jurlander and Troels Holz Borch and Søren Kjær Petersen and Marco Donia and Louise Guldbrandt and Rasmus Friis and Adam Andrzej Luczak and Henrik Schmidt and Christina Ruhlmann and Lars Bastholt and Eva Ellebaek and Inge Marie Svane},
year = {2026},
journal = {European Journal of Cancer},
doi = {10.1016/j.ejca.2026.117789},
url = {https://doi.org/10.1016/j.ejca.2026.117789}
}RIS
TY - JOUR TI - Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact AU - Rebecca Schou Jurlander AU - Troels Holz Borch AU - Søren Kjær Petersen AU - Marco Donia AU - Louise Guldbrandt AU - Rasmus Friis AU - Adam Andrzej Luczak AU - Henrik Schmidt AU - Christina Ruhlmann AU - Lars Bastholt AU - Eva Ellebaek AU - Inge Marie Svane PY - 2026 JO - European Journal of Cancer DO - 10.1016/j.ejca.2026.117789 UR - https://doi.org/10.1016/j.ejca.2026.117789 ER -
APA
Jurlander, R. S., Borch, T. H., Petersen, S. K., Donia, M., Guldbrandt, L., Friis, R., Luczak, A. A., Schmidt, H., Ruhlmann, C., Bastholt, L., Ellebaek, E., & Svane, I. M. (2026). Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117789
Source records
- crossref · retrieved 2026-11-07T22:42:29.185Z